Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy and Safety of GS-7977+Ribavirin for 12 Weeks in Treatment Naive and Treatment Experienced Subjects With Chronic Genotype 2 or 3 HCV Infection.
Brief Summary: This study will evaluate the safety, tolerability, and antiviral efficacy of GS-7977 with ribavirin (RBV) in participants with genotype 2 or 3 hepatitis C virus (HCV) infection.


Options:
A: Arm Label: 24-wk Vaniprevir 600 mg + Peg-IFN/RBV; Type: EXPERIMENTAL; Interventions: Drug: Vaniprevir, Drug: Pegylated Interferon (Peg-IFN), Drug: Ribavirin (RBV) | Arm Label: 24-wk Vaniprevir 600 mg + 24-wk PBO + Peg-IFN/RBV; Type: EXPERIMENTAL; Interventions: Drug: Vaniprevir, Drug: Pegylated Interferon (Peg-IFN), Drug: Ribavirin (RBV), Drug: Placebo (PBO) | Arm Label: 48-wk Vaniprevir 300 mg + Peg-IFN/RBV; Type: EXPERIMENTAL; Interventions: Drug: Vaniprevir, Drug: Pegylated Interferon (Peg-IFN), Drug: Ribavirin (RBV) | Arm Label: 48-wk Vaniprevir 600 mg + Peg-IFN/RBV; Type: EXPERIMENTAL; Interventions: Drug: Vaniprevir, Drug: Pegylated Interferon (Peg-IFN), Drug: Ribavirin (RBV) | Arm Label: 48-wk PBO + Peg-IFN/RBV; Type: PLACEBO_COMPARATOR; Interventions: Drug: Pegylated Interferon (Peg-IFN), Drug: Ribavirin (RBV), Drug: Placebo (PBO) | Intervention Type: DRUG; Name: Vaniprevir; Assigned to Arm(s): 24-wk Vaniprevir 600 mg + 24-wk PBO + Peg-IFN/RBV, 24-wk Vaniprevir 600 mg + Peg-IFN/RBV, 48-wk Vaniprevir 300 mg + Peg-IFN/RBV, 48-wk Vaniprevir 600 mg + Peg-IFN/RBV | Intervention Type: DRUG; Name: Pegylated Interferon (Peg-IFN); Assigned to Arm(s): 24-wk Vaniprevir 600 mg + 24-wk PBO + Peg-IFN/RBV, 24-wk Vaniprevir 600 mg + Peg-IFN/RBV, 48-wk PBO + Peg-IFN/RBV, 48-wk Vaniprevir 300 mg + Peg-IFN/RBV, 48-wk Vaniprevir 600 mg + Peg-IFN/RBV | Intervention Type: DRUG; Name: Ribavirin (RBV); Assigned to Arm(s): 24-wk Vaniprevir 600 mg + 24-wk PBO + Peg-IFN/RBV, 24-wk Vaniprevir 600 mg + Peg-IFN/RBV, 48-wk PBO + Peg-IFN/RBV, 48-wk Vaniprevir 300 mg + Peg-IFN/RBV, 48-wk Vaniprevir 600 mg + Peg-IFN/RBV | Intervention Type: DRUG; Name: Placebo (PBO); Assigned to Arm(s): 24-wk Vaniprevir 600 mg + 24-wk PBO + Peg-IFN/RBV, 48-wk PBO + Peg-IFN/RBV
B: Arm Label: Placebo 12 Weeks (GT2/3); Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo to match SOF, Drug: Placebo to match RBV | Arm Label: SOF 12 Weeks (GT2/3); Type: EXPERIMENTAL; Interventions: Drug: SOF, Drug: RBV | Arm Label: SOF 24 Weeks (GT3); Type: EXPERIMENTAL; Interventions: Drug: SOF, Drug: RBV | Intervention Type: DRUG; Name: SOF; Assigned to Arm(s): SOF 12 Weeks (GT2/3), SOF 24 Weeks (GT3) | Intervention Type: DRUG; Name: RBV; Assigned to Arm(s): SOF 12 Weeks (GT2/3), SOF 24 Weeks (GT3) | Intervention Type: DRUG; Name: Placebo to match SOF; Assigned to Arm(s): Placebo 12 Weeks (GT2/3) | Intervention Type: DRUG; Name: Placebo to match RBV; Assigned to Arm(s): Placebo 12 Weeks (GT2/3)
C: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: BMS-791325, Drug: Placebo | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Drug: BMS-791325, Drug: Placebo | Arm Label: 3; Type: EXPERIMENTAL; Interventions: Drug: BMS-791325, Drug: Placebo | Arm Label: 4; Type: EXPERIMENTAL; Interventions: Drug: BMS-791325, Drug: Placebo | Intervention Type: DRUG; Name: BMS-791325; Assigned to Arm(s): 1, 2, 3, 4 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): 1, 2, 3, 4
D: Arm Label: PegIFN/RBV; Type: ACTIVE_COMPARATOR; Interventions: Drug: PegIFN/RBV | Arm Label: BI 201335 for 12 or 24 weeks; Type: EXPERIMENTAL; Interventions: Drug: PegIFN/RBV, Drug: BI 201335 | Arm Label: Placebo and PegIFN/RBV; Type: ACTIVE_COMPARATOR; Interventions: Drug: PegIFN/RBV, Drug: Placebo | Intervention Type: DRUG; Name: PegIFN/RBV; Assigned to Arm(s): BI 201335 for 12 or 24 weeks, PegIFN/RBV, Placebo and PegIFN/RBV | Intervention Type: DRUG; Name: BI 201335; Assigned to Arm(s): BI 201335 for 12 or 24 weeks | Intervention Type: DRUG; Name: BI 201335; Assigned to Arm(s): BI 201335 for 12 or 24 weeks | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo and PegIFN/RBV

Answer: B